

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 374582000120	Application Number: To Be Assigned Continuation in Part of 09/672,109
	Applicant: Anthony L. ALMADA	
	Filing Date: Herewith	Group Art Unit: To Be Assigned
	Mailing Date: January 10, 2002	

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	10/08/1991	5,055,460	Friedlander	—	—	
	2.	02/08/1994	5,284,873	Salinero-Rodero et al.	—	—	
	3.	03/21/2000	6,039,950	Khwaja et al.	—	—	
	4.	03/13/2001	6,200,573	Locke	—	—	
	5.	03/27/2001	6,207,694	Murad	—	—	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	6.	01/07/1988	0 250 953 B1	EPO	—	—	
	7.	06/17/1983	2 480 754	France	—	—	Abstract

OTHER DOCUMENTS *(including author, title, Date, Pertinent Pages, Etc.)*

Examiner Initials	Ref. No.	Title
	8.	(July 22, 1996) Product Allert Bulletin Abstract Titled Max Dietary Supplement and Plan.
	9.	(December 21, 1992) "Product Allert Bulletin Abstract Titled Herbal Bio-Therapy Nutritional Formula.
	10.	Astrup, Arne <i>et al.</i> (1992). "The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial" <i>Int. J. Obes. Relat. Metab. Disord.</i> 16:269-277.
	11.	Astrup, A. and Toubro S. (1993). "Thermogenic, metabolic, and cardiovascular responses to ephedrine and caffeine in man" <i>Int. J. Obes. Relat. Metab. Disord.</i> 17 (Suppl. 1):S41-S43.
	12.	Breum, Leif <i>et al.</i> (1994). "Comparison of an ephedrine/caffeine combination and dexfenfluramine in the treatment of obesity. A double-blind multi-centre trial in general practice" <i>Int. J. Obes. Relat. Metab. Disord.</i> 18:99-103.

EXAMINER:

DATE CONSIDERED: 11/5/02

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket Number 374582000120	Application Number: To Be Assigned Continuation in Part of 09/672,109
INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Applicant: Anthony L. ALMADA	
		Filing Date: Herewith	Group Art Unit: To Be Assigned
		Mailing Date: January 10, 2002	
	13.	Docherty, James R. and Starke, Klaus (1981). "Postsynaptic alpha-adrenoceptor subtypes in rabbit blood vessels and rat anococcygeus muscle studied <i>in vitro</i> " <i>J. Cardiovasc. Pharmacol.</i> 3(4): 854-866.	
	14.	Goepel, Mark <i>et al.</i> (1999). "Saw palmetto extracts potently and noncompetitively inhibit human alpha ₁ -adrenoceptors <i>in vitro</i> " <i>The Prostate</i> 38:208-215.	
	15.	Gurley, Bill J. <i>et al.</i> (1998). "Ephedrine pharmacokinetics after the ingestion of nutritional supplements containing <i>Ephedra sinica</i> (ma huang)" <i>Ther. Drug Monit.</i> 20:439-445.	
	16.	Gutierrez M. <i>et al.</i> (1996). "Mechanisms involved in the spasmolytic effect of extracts from <i>Sabal serrulta</i> fruit on smooth muscle" <i>General Pharmacology</i> 27(1):171-176.	
	17.	Hamed, A.T. <i>et al.</i> (1983). "Pharmacological characterization of alpha-adrenoreceptor subtypes in rat isolated thoracic aorta" <i>J. Auton. Pharmacol.</i> 3:265-273.	
	18.	Langer, S.Z. and Hicks, P.E. (1984). "Alpha-adrenoreceptor subtypes in blood vessels: physiology and pharmacology" <i>J. Cardiovasc. Pharmacol.</i> 6 (Suppl. 4):S547-558.	
	19.	Lasagna, Louis (1988). <u>Phenylpropanolamine. A Review</u> John Wiley & Sons, Table of Contents, pp. IX-XV.	
	20.	Malchow-Møller, Axel <i>et al.</i> (1981). "Ephedrine as an anorectic: the story of the 'Elsinore pill'" <i>Int. J. Obes.</i> 5:183-187.	
	21.	<i>Morb. Mortal. Wkly. Rep.</i> (1996). "Adverse events associated with ephedrine-containing products - Texas, December 1993-September 1995" 45(32):689-693.	
	22.	Nadir, Abdul <i>et al.</i> (1996). "Acute hepatitis associated with the use of a Chinese herbal product, Ma-huang" <i>Am. J. Gastroenterol.</i> 91(7):1436-1438.	
	23.	Nasser, J.A. <i>et al.</i> (1999). "Efficacy trial for weight loss of an herbal supplement of Ma Huang and Guarana" <i>FASEB J.</i> 13(5):A874, Abstract No. 660.8.	
	24.	Pasquali, R. <i>et al.</i> (1985). "A controlled trial using ephedrine in the treatment of obesity" <i>Int. J. Obes.</i> 9:93-98.	
	25.	Powell, Thomas <i>et al.</i> (1998). "Ma-Huang strikes again: ephedrine nephrolithiasis" <i>Am. J. Kidney Dis.</i> 32(1):153-159.	
	26.	Turek, P.J. <i>et al.</i> Department of Urology, University of California, San Francisco, CA. (1996). "An <i>in vivo</i> microsurgical animal model of seminal vesicle contractility: the effects of alpha-adrenergic agents" <i>Annual Meeting of the American Society of Reproductive Medicine</i> pp. S195-S196, Abstract No. P-222.	
	27.	White, Laura M. <i>et al.</i> (1997). "Pharmacokinetics and cardiovascular effects of Ma-Huang (<i>Ephedra sinica</i>) in normotensive adults" <i>J. Clin. Pharmacol.</i> 37:116-122.	
	28.	Zaacks, Stephen M. <i>et al.</i> (1999). "Hypersensitivity myocarditis associated with ephedra use" <i>J. Toxicol. Clin. Toxicol.</i> 37(4):485-489.	
EXAMINER: C. L. Tate		DATE CONSIDERED: 11/5/02	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			



Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Docket Number 374582000120	Application Number 10/044,645
	Applicant Anthony L. ALMADA	
	Filing Date January 10, 2002	Group Art Unit To Be Assigned
	Mailing Date March 21, 2002	

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	10/08/1991	5,055,460	Friedlander	—	—	
	2.	02/08/1994	5,284,873	Salinero-Rodero et al.	—	—	
	3.	03/21/2000	6,039,950	Khwaja et al.	—	—	
	4.	03/13/2001	6,200,573 B1	Locke	—	—	
	5.	03/27/2001	6,207,694 B1	Murad	—	—	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	6.	01/07/1988	0 250 953 B1	EPO	—	—	
	7.	06/17/1983	2 480 754	France	—	—	Abstract

OTHER DOCUMENTS


(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	8.	Astrup, A. and Toubro S. (1993). "Thermogenic, metabolic, and cardiovascular responses to ephedrine and caffeine in man" <i>Int. J. Obes. Relat. Metab. Disord.</i> 17 (Suppl. 1):S41-S43.
	9.	Astrup, Arne <i>et al.</i> (1992). "The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial" <i>Int. J. Obes. Relat. Metab. Disord.</i> 16:269-277.
	10.	Breum, Leif <i>et al.</i> (1994). "Comparison of an ephedrine/caffeine combination and dexfenfluramine in the treatment of obesity. A double-blind multi-centre trial in general practice" <i>Int. J. Obes. Relat. Metab. Disord.</i> 18:99-103.
	11.	Docherty, James R. and Starke, Klaus (1981). "Postsynaptic alpha-adrenoceptor subtypes in rabbit blood vessels and rat anococcygeus muscle studied <i>in vitro</i> " <i>J. Cardiovasc. Pharmacol.</i> 3(4): 854-866.
	12.	Goepel, Mark <i>et al.</i> (1999). "Saw palmetto extracts potently and noncompetitively inhibit human alpha ₁ -adrenoceptors <i>in vitro</i> " <i>The Prostate</i> 38:208-215.
	13.	Gurley, Bill J. <i>et al.</i> (1998). "Ephedrine pharmacokinetics after the ingestion of nutritional

EXAMINER: C. R. Tate

DATE CONSIDERED: 11/5/02

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



Form PTO-1449

Docket Number 374582000120

Application Number 10/044,645

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Anthony L. ALMADA

Filing Date January 10, 2002

Group Art Unit ~~To Be Assigned~~ 1654

Mailing Date March 21, 2002

		supplements containing <i>Ephedra sinica</i> (ma huang)" <i>Ther. Drug Monit.</i> 20:439-445.
14.		Gutierrez M. <i>et al.</i> (1996). "Mechanisms involved in the spasmolytic effect of extracts from <i>Sabal serrulta</i> fruit on smooth muscle" <i>General Pharmacology</i> 27(1):171-176.
15.		Hamed, A.T. <i>et al.</i> (1983). "Pharmacological characterization of alpha-adrenoreceptor subtypes in rat isolated thoracic aorta" <i>J. Auton. Pharmacol.</i> 3:265-273.
16.		Langer, S.Z. and Hicks, P.E. (1984). "Alpha-adrenoreceptor subtypes in blood vessels: physiology and pharmacology" <i>J. Cardiovasc. Pharmacol.</i> 6 (Suppl. 4):S547-558.
17.		Lasagna, Louis (1988). <u>Phenylpropanolamine. A Review</u> John Wiley & Sons, Table of Contents, pp. IX-XV.
18.		Malchow-Møller, Axel <i>et al.</i> (1981). "Ephedrine as an anorectic: the story of the 'Elsinore pill'" <i>Int. J. Obes.</i> 5:183-187.
19.		<i>Morb. Mortal. Wkly. Rep.</i> (1996). "Adverse events associated with ephedrine-containing products - Texas, December 1993-September 1995" 45(32):689-693.
20.		Nadir, Abdul <i>et al.</i> (1996). "Acute hepatitis associated with the use of a Chinese herbal product, Ma-huang" <i>Am. J. Gastroenterol.</i> 91(7):1436-1438.
21.		Nasser, J.A. <i>et al.</i> (1999). "Efficacy trial for weight loss of an herbal supplement of Ma Huang and Guarana" <i>FASEB J.</i> 13(5):A874, Abstract No. 660.8.
22.		Pasquali, R. <i>et al.</i> (1985). "A controlled trial using ephedrine in the treatment of obesity" <i>Int. J. Obes.</i> 9:93-98.
23.		Powell, Thomas <i>et al.</i> (1998). "Ma-Huang strikes again: ephedrine nephrolithiasis" <i>Am. J. Kidney Dis.</i> 32(1):153-159.
24.		Product Allert Bulletin Abstract. (December 21, 1992). "Herbal Bio-Therapy Nutritional Formula for Men."
25.		Product Allert Bulletin Abstract. (July 22, 1996). "Max Dietary Supplement and Plan."
26.		Turek, P.J. <i>et al.</i> Department of Urology, University of California, San Francisco, CA. (1996). "An <i>in vivo</i> microsurgical animal model of seminal vesicle contractility: the effects of alpha-adrenergic agents" <i>Annual Meeting of the American Society of Reproductive Medicine</i> pp. S195-S196, Abstract No. P-222.
27.		White, Laura M. <i>et al.</i> (1997). "Pharmacokinetics and cardiovascular effects of Ma-Huang (<i>Ephedra sinica</i>) in normotensive adults" <i>J. Clin. Pharmacol.</i> 37:116-122.
28.		Zaacks, Stephen M. <i>et al.</i> (1999). "Hypersensitivity myocarditis associated with ephedra use" <i>J. Toxicol. Clin. Toxicol.</i> 37(4):485-489.

EXAMINER:

C. R. Tate

DATE CONSIDERED:

11/5/02

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.